RetractedTrialArchives of virology2020

High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life experience.

Ebada Mohamed Said et al.PubMed ↗Publisher ↗

No numbers read from the abstract.